TMED10

Across TCGA pan-cancer cohorts, TMED10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMED10 data layer compared with 30 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TMED10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMED10 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where TMED10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	12	view →
CCRCC	OS	Median	All	0.629	1.000	.002	10	view →
HNSC	DFS	Median	III,IV	0.887	0.723	.022	4	view →
GBM	DFS	Quartile	All	0.272	0.473	.047	2	view →
LUAD	DFS	Median	All	0.898	1.000	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMED10–PDAC (DFS)

Open the PDAC breakdown →